FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Cormack Scott Daniel 		2. Issuer Name and Ticker or Trading Symbol

ONCOGENEX PHARMACEUTICALS, INC. [ OGXI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

400-1001 W. BROADWAY 		3. Date of Earliest Transaction (MM/DD/YYYY)

1/10/2017
(Street)

VANCOUVER, A1 V6H 4B1
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   1/10/2017     M    20312   (1) A $0.00   149740   D    
Common Stock   1/10/2017     F    9690   (2) D $0.63   140050   D    
Common Stock   1/10/2017     M    10312   (1) A $0.00   84055   I   By Spouse  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU)     (3) 1/10/2017     M         4687      (4) 1/31/2017   Common Stock   4687   $0.00   0   D    
Restricted Stock Unit (RSU)     (3) 1/10/2017     M         6250      (5) 4/13/2018   Common Stock   6250   $0.00   6250   D    
Restricted Stock Unit (RSU)     (3) 1/10/2017     M         9375      (6) 6/18/2019   Common Stock   9375   $0.00   18750   D    
Restricted Stock Unit     (3) 1/10/2017     M         2500      (4) 1/31/2017   Common Stock   2500   $0.00   0   I   By Spouse  
Restricted Stock Unit (RSU)     (3) 10/10/2017     M         3125      (5) 4/13/2018   Common Stock   3125   $0.00   3125   I   By Spouse  
Restricted Stock Unit (RSU)     (3) 10/10/2017     M         4687      (6) 6/18/2019   Common Stock   4687   $0.00   9375   I   By Spouse  

Explanation of Responses:
( 1)  Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
( 2)  Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
( 3)  Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
( 4)  Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
( 5)  Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
( 6)  Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Cormack Scott Daniel
400-1001 W. BROADWAY
VANCOUVER, A1 V6H 4B1 		X
President and CEO

Signatures
Sandra Thomson as attorney-in-fact for Scott Cormack 1/12/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Achieve Life Sciences Charts.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Achieve Life Sciences Charts.